Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Reports Prelim 2015 Earnings Below Analyst Estimates

NEW YORK (GenomeWeb) – Sequenom today reported preliminary 2015 revenue of $128 million, below analyst estimates of $130 million.

The company also said it accessioned 42,000 total commercial diagnostic test samples in the fourth quarter, up from 41,000 in the third quarter. Of the 42,000 tests, 37,300 were noninvasive prenatal test samples. In addition, Sequenom accessioned 3,000 of its MaterniT Genome test in Q4, the assay's first full quarter of sales.

Sequenom further reported it has approximately $76 million in total cash, cash equivalents, and marketable securities as of Dec. 31, 2015.

The company will provide its complete results for the Q4 and FY2015 on Mar. 2, 2016, and will provide guidance for 2016 at that time. 

Sequenom recently announced it would cut 20 percent of its workforce and divest a lab in North Carolina as part of an organizational restructuring effort.

The company's shares were up more than 3 percent at $1.39 in mid-afternoon trading on the Nasdaq.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.